Sarcomas and Histiocytosis
Research Program
Leaders
Where we are
SJD Barcelona Children's Hospital
Related websites
SJD Barcelona Children’s Hospital Our group aims to generate a knowledge base on developmental sarcomas and Langerhans cell histiocytosis (LCH) with a view to improving diagnosis, prognosis and treatment.
Our specific activities are:
· The study of the aetiology of sarcomas and LCH and the phenotypic and genotypic characterisation of the different clinical subtypes.
· The investigation of the existence of cancer stem cells or progenitor cells.
· Improving treatments for patients with sarcomas by studying preclinical pharmacology.
· The development of IGF-1R-targeted therapies for sarcoma.
· The study of molecular pathways and therapies aimed at histiocytosis.
Since 2014 we have been a consolidated AGAUR research group (Government of Catalonia, references 2014 SGR 1398 and 2017 SGR 1672).
Scientific objectives
- To develop innovative pharmacological treatments for extracranial paediatric solid tumours such as Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma and LCH.
- To describe the cell of origin in Ewing's sarcoma and to develop experimental models to reproduce the tumourigenesis process.
Area/Field of expertise
Development of cell models and patient-derived xenografts (PDX) of paediatric solid tumours (rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, Wilms tumour, germ cell tumours) from biobank samples.
Efficacy tests of anticancer agents used to treat paediatric solid tumours.
Epigenomics and chromatin conformation studies using chip-Seq, CHIP-CHIP, HI-Seq.
Group members
-
Jefe de Grupo Senior
-
Maria Inmaculada Hernandez Muñoz
Investigador colaborador
-
Investigador pre-doc
-
Investigador post-doc
-
Ayudante de investigación
-
Ayudante de investigación
-
Investigador
-
Investigador
-
Ayudante de investigación
-
Investigador pre-doc
-
Investigador
-
Ayudante de investigación
-
Investigador post-doc
-
Ayudante de investigación
-
Investigador post-doc
-
Técnico
-
Técnico
-
Carlos Javier Rodriguez Hernandez
Investigador post-doc
-
Investigador
-
Investigador
-
Ayudante de investigación
-
Pablo Táboas Outón
Investigador pre-doc
Last Publications
- Rössler J, Eulalia Baselga Torres, Davila V, Celis-Passini V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM and Kapp FG Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. PEDIATRIC BLOOD & CANCER . 68(8): e28936.
- Castillo-Ecija H, Pascual-Pastó G, Pérez-Jaume S, Resa-Pares C, Vilà-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farres M, Muñoz-Aznar O, Salvador-Marcos N, Cuadrado-Vilanova M, Gene-Olaciregui N, Balaguer-Lluna L, Burgueño V, Vicario FJ, Manzanares-Quintela A, Castañeda-Heredia A, Santa-María López V, Cruz-Martínez O, Celis-Passini V, Morales-La Madrid A, Garraus-Oneca M, Gorostegui M, Vancells M, Carrasco-Torrents R, Krauel L, Torner-Rubies F, Suñol M, Lavarino C, Mora J and Montero-Carcaboso A Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas. JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 7(4): 338-349.
- Carrere X, Pinto N, Gene-Olaciregui N, Galluzzo L, Rossetti E, Celis-Passini V, Salvador-Marcos N, Chantada G, Braier J, Lavarino C and Felizzia G High prevalence of BRAF(V600E) in patients with cholestasis, sclerosing cholangitis or liver fibrosis secondary to Langerhans cell histiocytosis. PEDIATRIC BLOOD & CANCER . 68(7): e29115.
Projects
- Project name:
- Influencia del contexto epigenético en la edad como factor pronóstico en Ewing Sarcoma
- Leader
- Jaume Mora Graupera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI20/00179
- Starting - finishing date:
- 2021 - 2023
- Project name:
- Ayudas para contratos Ramón y Cajal (RYC) 2019. Beneficiario: Alexandra Avgustinova
- Leader
- Alexandra Avgustinova
- Funding entities:
- Ministerio de Economía Y Competitividad (MINECO)
- Code
- RYC2019-027738-I
- Starting - finishing date:
- 2020 - 2025
- Project name:
- Unveiling the Ewing sarcoma cell of origin: a multistep transformation process that involves prenatal genetic and postnatal epigenetic mechanisms
- Leader
- Jaume Mora Graupera
- Funding entities:
- Fundació La Marató de TV3
- Code
- 201928-30
- Starting - finishing date:
- 2020 - 2023
Theses
-
Combined therapies for neuroblastoma based on the activation of the calcium sensing receptor
- Author
- Gonçalves Alves, Eliana Carolina
- Institution
- UNIVERSIDAD DE BARCELONA
-
Polycomb and KDM6A Roles in the Epigenetic Dynamics of Ewing Sarcoma Tumorigenesis”
- Author
- Figuerola Bou, Elisabet
- Institution
- UNIVERSIDAD DE BARCELONA
-
Influence of the epigenetic background in the generation and treatment of Ewing Sarcoma
- Author
- Sanchez Jimenez, Maria
- Institution
- UNIVERSIDAD DE BARCELONA
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
-
Gene crucial for growth of Ewing sarcoma uncovered
Researchers at the Institut de Recerca Sant Joan de Déu in collaboration with those at Centre for Genomic Regulation have discovered that RING1B is a critical gene for the development of Ewing sarcoma, a rare type of developmental cancer that presents in bones and soft tissues.